TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01957137

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim® (Device Programming)

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim® (Device Programming)

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim® (Device Programming)

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim® (Device Programming)

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim® (Device Programming)
Study: NCT01395784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
Study: NCT04409704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: 10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week, 20-30 sessions.
Study: NCT02591719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro magnetic stimulator (HF rTMS)
Description: Most activated area from fNIRS findings: Perilesional Broca's area. Use the true coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagPro magnetic stimulator (sham)
Description: Most activated area from fNIRS findings: Perilesional Broca's area. Use the sham coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
Study: NCT06770894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: The study population will be randomly allocated in either intervention or placebo arm (1:1). Treatment (sitagliptin 100 mg) and placebo will be provide in identical packages by an experienced independent pharmacist. The recommended intake is one tablet a day, equivalent to sitagliptin 100 mg in the active-treated group, for the duration of the study (52 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo tablets 1 a day, provided in identical blisters.
Study: NCT02591719

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagPro magnetic stimulator (LF rTMS)
Description: Most activated area from fNIRS findings: Contralesional homologs of Broca's area.~Use the true coil. Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
Study: NCT01656772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vdrive Lasso navigation
Description: Remote robotic Lasso navigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lasso navigation
Description: Manually maneuver a Lasso catheter
Study: NCT02613455

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shock wave therapy
Description: Following clearance, patients will be booked for ESWT in the operating room either WRNMMC or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24kV, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog (triamcinolone)
Description: patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 1% (lidocaine HCl 20mg)
Description: patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
Study: NCT02947867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aganirsen
Description: aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aganirsen
Description: aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aganirsen
Description: aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
Study: NCT04208425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Personality
Description: The intervention includes five components: 1. An introduction to the brain, including a lesson on the concept of neuroplasticity, describing how and why our behaviors are controlled by thoughts and feelings in their brains, which have potential for change; 2. Written testimonials from older youths who describe their beliefs that people's personal traits (e.g., sadness, anxiety) are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits (i.e., a self-persuasion exercise).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sharing Feelings Intervention
Description: The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the web-based growth mindset intervention; it also mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
Study: NCT01774422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal CO2 removal device

Intervention type: DEVICE
Group type: OTHER
Intervention: Extracorporeal CO2 removal device
Study: NCT01395784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone
Description: A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
Study: NCT02900989

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Suicide screening
Description: Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.~The study had to be declared as an interventional study according to French law.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Suicide screening
Description: Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.~The study had to be declared as an interventional study according to French law.
Study: NCT06771271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7200220
Description: RO7200220 was administered as IVT injection.
Study: NCT00412776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxinium
Description: 700 µg Proxinium, once weekly until complete resolution of all target tumours or radiographic tumour progression
Study: NCT03987204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine will be started and titrated to heart rate slowing of 20 bpm or greater, or an increase in pacing.
Study: NCT03684135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetics
Description: Tendre Caresse au cold cream body cream from Cosmétosource Crème de douche face and body cleanser from Cosmétosource
Study: NCT06771271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7200220
Description: RO7200220 was administered as IVT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7200220
Description: RO7200220 was administered as IVT injection.
Study: NCT04508907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavyret
Description: Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients
Study: NCT02628860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject (Ferric Carboxymaltose)
Description: Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50 Kg .~Study drug may be administered as IV drip infusion or IV undiluted bolus injection.
Study: NCT03711903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).
Description: The study drug, CN-105 is supplied in amber glass vials containing 4 mL of a concentrated 12.5-mg/mL clear-to-slightly-yellow solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: normal saline
Study: NCT02949830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givosiran
Description: Givosiran by subcutaneous (SC) injection.
Study: NCT06771271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7200220
Description: RO7200220 was administered as IVT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab was administered as IVT injection.
Study: NCT02440581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Study: NCT00611494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: Gradual optimization of drug dosage, as clinically tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-MPS
Description: Conversion from MMF to EC-MPS. Gradual optimization of drug dosage, as clinically tolerated.
Study: NCT01811511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chungkookjang

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chungkookjang

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02886299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Study: NCT01422954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine prophylaxis
Description: Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks. On day 0, day 3, day 7 and day 10, this group will receive a placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mefloquine prophylaxis
Description: Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine prophylaxis
Description: Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunization
Description: Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Immunization
Description: Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization
Description: Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Human Malaria Infection
Description: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Controlled Human Malaria Infection
Description: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Controlled Human Malaria Infection
Description: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Malarone
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study: NCT04373460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 convalescent plasma
Description: SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasma from a volunteer donor
Description: Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
Study: NCT01042444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GARDEX™
Description: GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.~The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires.
Study: NCT02527356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ride-On Cars with Standing Posture (ROC-Stand)
Description: The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ride-On Cars with Standing Postures (ROC-Sit)
Description: Most of the guidelines are similar with ROC-Stand, except for the posture of driving. The training time and period is the same as ROC-Stand. The two 30-minute driving sessions can also be divided into 4 times of 15-minute sessions, depending on the child's standing ability with supported condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular Therapy Program
Description: The research team will ask caregivers to identify goals (before intervention), and measure progress using goal-attainment scaling (GAS). The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. In addition, they will receive training program in a hospital for 2 hours/per session, 2 sessions/per week for a total of 12-week intervention. The participants will also experience the two 30-minute car driving sessions during the whole 2-hour training. The difference between the regular therapy group and the two ROC groups is the experience of car driving is controlled by the therapist, i.e. passive locomotion. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance for 1 hour/per session, 1 session/per week during the 12-week intervention phase.
Study: NCT00700804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Protein Diet
Description: High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
Study: NCT00299988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02116621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trialist Intervention
Description: Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone
Study: NCT02972320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: temozolomide maintain therapeutic
Study: NCT01983644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECO flow restoration device
Description: RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire FR flow restoration device
Description: Solitaire FR flow restoration device has been approved by the FDA and CFDA.
Study: NCT02452502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
Study: NCT01992822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental pain induction
Description: application of a pre-fixed pressure (160 kPa) on the forearm.
Study: NCT04590456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEMF
Description: group A received 60 minutes of traditional program physical therapy which consisted of passive range of motion, stretching,proprioception, isotonic and isometric and 20 minutes of placebo treatment using PEMF, while group B received the same traditional physical therapy program given to the control group in addition of 20 minutes of PEMF therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEMF
Description: group A received 60 minutes of traditional program physical therapy which consisted of passive range of motion, stretching,proprioception, isotonic and isometric and 20 minutes of placebo treatment using PEMF, while group B received the same traditional physical therapy program given to the control group in addition of 20 minutes of PEMF therapy
Study: NCT03540186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigenorm Antivir
Description: 1 capsule of Epigenorm Antivir twice daily for 3 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture involves inserting sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: no less than 15 sessions, based on the physician discretion
Study: NCT04942392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital dance for PD
Description: The digital dance class was held via Zoom. The class was scheduled once a week for 60 min and consisted of 10 sessions. A professional, certified Dance for PD and experienced dance instructor was teaching the dance class. The dance classes followed the Dance for PD protocol yet was adjusted to fit the digital zoom format.
Study: NCT03653520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: 5 or 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: 5 or 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 50mg or 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 1 or two tabs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKO melt
Description: 1 or 2 MKO melts
Study: NCT02277444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab 80 mg/m\^2 IV infusion at Weeks 0, 4, and every 8 weeks through Week 244. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m\^2 every 8 weeks after completion of the Week 252 assessments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate BSA-based dose (10 to 30 mg/m\^2 per week for participants with BSA \<1.67 m\^2, or minimum of 15 mg/week for participants with BSA \>=1.67 m\^2) weekly at least through Week 28.